Comparison of pharmacist managed anticoagulation with usual medical care in a family medicine clinic

BMC Family Practice

Volumn 12, Issue , 2011, Pages

  Young, Stephanie ^a   Bishop, Lisa ^a   Twells, Laurie ^a   Dillon, Carla ^a   Hawboldt, John ^a   O'Shea, Patrick ^a,b  

^a MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^b Newfoundland Drive Family Practice ^*  (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT;

AGED; ARTICLE; COHORT ANALYSIS; COMPARATIVE STUDY; FEMALE; GENERAL PRACTICE; HUMAN; MALE; MIDDLE AGED; OUTPATIENT DEPARTMENT; PHARMACY; RETROSPECTIVE STUDY;

AGED; AMBULATORY CARE FACILITIES; ANTICOAGULANTS; COHORT STUDIES; FAMILY PRACTICE; FEMALE; HUMANS; MALE; MIDDLE AGED; PHARMACEUTICAL SERVICES; RETROSPECTIVE STUDIES;

EID: 80051658000     PISSN: None     EISSN: 14712296     Source Type: Journal    
DOI: 10.1186/1471-2296-12-88     Document Type: Article

References (21)

1. Executive summary: American College of Chest Physicians Evidence- Based Clinical Practice Guidelines. Hirsh J, Guyatt G, Albers GW, Harrington R, Schünemann HJ, American College of Chest Physicians, Chest 8 2008 133 Suppl 71 109 Erratum in: Chest 2008;134:892 10.1378/chest.08-0693 (Pubitemid 351892961)
2. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G, American College of Chest Physicians, Chest 2008 133 Suppl 160 198 10.1378/chest.08-0670 (Pubitemid 351892967)
3. XARELTO (rivaroxaban) Product Monograph. http://www.bayer.ca/files/ XARELTO-PM-ENG-10SEP2008-119111.pdf?#
4. Pradax (dabigatran) Product Monograph. http://www.boehringer-ingelheim. ca/content/dam/internet/opu/ca-EN/documents/humanhealth/product-monograph/ Pradax-pm.pdf
5. Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM, the ROCKET AF Steering Committee for the ROCKET AF Investigators, N Engl J Med 2011 http://www.nejm.org/doi/full/10.1056/NEJMoa1009638
6. Dabigatran versus warfarin in patients with atrial fibrillation. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L, RE-LY Steering Committee and Investigators, N Engl J Med 2009 361 1139 1151 10.1056/NEJMoa0905561 19717844
7. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein- DVT Dose-Ranging Study. Buller HR, Lensing AW, Prins MH, Agnelli G, Cohen A, Gallus AS, Misselwitz F, Raskob G, Schellong S, Segers A, Einstein-DVT Dose-Ranging Study investigators, Blood 2008 112 2242 2247 10.1182/blood-2008-05-160143 18621928
8. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, Baanstra D, Schnee J, Goldhaber SZ, RE-COVER Study Group, N Engl J Med 2009 361 2342 2352 10.1056/NEJMoa0906598 19966341
9. Comparing the quality of oral anticoagulant management by anticoagulation clinics and by family physicians: a randomized controlled trial. Wilson SJ, Wells PS, Kovacs MJ, Lewis GM, Martin J, Burton E, Anderson DR, CMAJ 2003 169 293 298 Erratum in: CMAJ 2004,170:451 12925422 (Pubitemid 37047057)
10. Management of Chinese patients on warfarin therapy in two models of anticoagulation service-a prospective randomized trial. Chan FW, Wong RS, Lau WH, Chan TY, Cheng G, You JH, Br J Clin Pharmacol 2006 62 601 609 10.1111/j.1365-2125.2006.02693.x 17061966 (Pubitemid 44571582)
11. Evaluation of a pharmacist-managed anticoagulation clinic: Improving patient care. Bungard TJ, Gardner L, Archer SL, Hamilton P, Ritchie B, Tymchak W, Tsuyuki RT, Open Med 2009 3 16 21 19946388
12. Comparison of two different models of anticoagulation management services with usual medical care. Rudd KM, Dier JG, Pharmacotherapy 2010 30 330 338 10.1592/phco.30.4.330 20334453
13. Comparison of an anticoagulation clinic with usual medical care: anticoagulation control, patient outcomes, and health care costs. Chiquette E, Amato MG, Bussey HI, Arch Intern Med 1998 158 1641 1647 10.1001/archinte.158.15. 1641 9701098 (Pubitemid 28371187)
14. Is long-term pharmacist-managed anticoagulation service efficient? A pragmatic randomized controlled trial. Lalonde L, Martineau J, Blais N, Montigny M, Ginsberg J, Fournier M, Berbiche D, Vanier MC, Blais L, Perreault S, Rodrigues I, Am Heart J 2008 156 148 154 10.1016/j.ahj.2008.02.009 18585510
15. Comparison of anticoagulation clinic patient outcomes with outcomes from traditional care in a family medicine clinic. Chamberlain MA, Sageser NA, Ruiz D, J Am Board Fam Pract 2001 14 16 21 11206689 (Pubitemid 33605759)
16. Shifts in expectations: evaluating physicians' perceptions as pharmacists become integrated into family practice. Farrell B, Pottie K, Woodend K, Yao V, Dolovich L, Kennie N, Sellors C, J Interprof Care 2010 24 80 9 10.3109/13561820903011968 19705320
17. Consensus guidelines for coordinated outpatient oral anticoagulation therapy management. Anticoagulation Guidelines Task Force. Ansell JE, Buttaro ML, Thomas OV, Knowlton CH, Ann Pharmacother 1997 31 604 615 9161658 (Pubitemid 27203962)
18. Outpatient management of oral vitamin K antagonist therapy: defining and measuring high-quality management. Phillips KW, Ansell J, Expert Rev Cardiovasc Ther 2008 6 57 70 10.1586/14779072.6.1.57 18095907
19. Statistics Canada Population of census metropolitan areas (2006 Census boundaries). http://www40.statcan.gc.ca/l01/cst01/demo05a-eng.htm
20. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis, J Thromb Haemost 2005 3 692 694 10.1111/j.1538-7836.2005.01204.x 15842354 (Pubitemid 41647882)
21. A method to determine the optimal intensity of oral anticoagulant therapy. Rosendaal FR, Cannegieter SC, van der Meer FJ, Brit E, Thromb Haemost 1993 69 236 239 8470047 (Pubitemid 23069000)